Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Recombinant Coagulation Factor VIII vs Xyntha in Hemophilia A
NCT04060836Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2019
- Primary completion
- Mar 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of moroctocog alfa in hemophilia A (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak plasma concentration (Cmax) - Single Dose, Area under the plasma concentration versus time curve (AUC) - Single Dose and 1 more. Status: unknown.
02
Drugs
moroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04060836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060836.